Enduring allogeneic marrow engraftment via nonspecific bone-marrow-derived regulating factors (MRF)

1981 ◽  
Vol 57 (1) ◽  
pp. 219-228 ◽  
Author(s):  
Walter Pierpaoli ◽  
Georges Jean-Marie Maestroni ◽  
Edgar Sache
Keyword(s):  
Bone Marrow ◽  
Allogeneic Marrow

scholarly journals Allogeneic Marrow Engraftment by Cross Circulation in Lethally Irradiated Dogs

Blood ◽  
1966 ◽  
Vol 28 (5) ◽  
pp. 692-707 ◽  
Author(s):  
R. B. EPSTEIN ◽  
T. C. GRAHAM ◽  
C. D. BUCKNER ◽  
J. BRYANT ◽  
E. D. THOMAS
Keyword(s):  
Bone Marrow ◽  
Peripheral Blood ◽  
Early Period ◽  
Severe Form ◽  
Allogeneic Bone ◽  
Female Partners ◽  
Secondary Disease ◽  
Total Body ◽  
Bone Marrow Engraftment ◽  
Allogeneic Marrow

Abstract Dogs given 1200 r of total body irradiation were cross-circulated with dogs having normal marrow function. Irradiated controls died in from 4 to 11 days with marrow aplasia. Dogs cross-circulated daily for 6 to 9 days showed histologic evidence of bone marrow repopulation after 1 week. Male dogs cross-circulated with female partners showed typical female drumsticks on mature granulocytes after repopulation had occurred. Cytogenetic studies of an irradiated male dog cross-circulated with a female partner showed all mitotable cells from the bone marrow and peripheral blood to be of female donor type. Allogeneic bone marrow engraftment was associated with an early and severe secondary syndrome which resulted in the death of the animals in the second week. When methotrexate was given, survival was increased to 3 weeks. It was concluded that (1) cross circulation provided leukocytes and platelets adequate for support during the period of radiation-induced marrow aplasia, (2) allogeneic marrow engraftment was produced consistently by cells transferred in the peripheral blood of the normal cross circulation partner, (3) the grafts were associated with an early and severe form of secondary disease, and (4) methotrexate given during the early period of engraftment reduced the severity of the secondary disease.

Treatment of lymphopenic hypogammaglobulinemia and bone marrow aplasia by transplantation of allogeneic marrow

1970 ◽  
Vol 9 (6) ◽  
pp. 589
Author(s):  
H J Meuwissen ◽  
R A Gatti ◽  
P I Terasaki ◽  
R Hong ◽  
R A Good
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Aplasia ◽  
Allogeneic Marrow

scholarly journals PECULIAR IMMUNOBIOLOGY OF BONE MARROW ALLOGRAFTS

1971 ◽  
Vol 134 (6) ◽  
pp. 1513-1528 ◽  
Author(s):  
Gustavo Cudkowicz ◽  
Michael Bennett
Keyword(s):  
Bone Marrow ◽  
X Rays ◽  
F1 Hybrid ◽  
Tissue Specific ◽  
Split Dose ◽  
First Case ◽  
Specific Antigens ◽  
Transplantation Antigens ◽  
Hybrid Mice ◽  
Allogeneic Marrow

F1 hybrid mice are capable of rejecting inbred parental strain bone marrow grafts after a single lethal exposure to X-rays. The incompatibility is genetically controlled by the Hybrid-histocompatibility-1 (Hh-1) locus in or near the D end of the Histocompatibility-2 (H-2) region. The onset of parental graft rejection begins 9–12 hr after transplantation and is completed by 24 hr. Maturation of hybrid resistance does not occur until the 22nd day of life. In adults, the resistance to parental marrow grafts can be temporarily abrogated or weakened by administration of cyclophosphamide or dead cultures of Corynebacterium parvum, acute supralethal exposures to radiation, or by split-dose irradiation with 6–37-day intervals. Parental marrow grafts elicit a transplantation reaction in irradiated F1 mice which is indistinguishable from that elicited in irradiated allogeneic (H-2-incompatible) hosts. Because of this immunogenetic similarity, the following question is raised: are the same or different alloantigens responsible for rejection of parental and allogeneic marrow grafts? In the first case, Hh-1 alleles would be recessive determinants of tissue-specific transplantation antigens, whereas in the second case they would be the determinants of parental- and tissue-specific antigens subject to genetic suppression in Hh-1 heterozygotes. Although the available evidence is not conclusive in excluding one of the two possibilities, it favors the concept that allograft reactivity to hemopoietic cells is elicited by recessive tissue-specific antigens.

scholarly journals Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumor-derived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts

Blood ◽  
1996 ◽  
Vol 87 (7) ◽  
pp. 3053-3060 ◽  
Author(s):  
LW Kwak ◽  
R Pennington ◽  
DL Longo
Keyword(s):  
Bone Marrow ◽  
T Cell ◽  
B Cell ◽  
Antitumor Effect ◽  
B Cell Lymphoma ◽  
Allogeneic Bone Marrow ◽  
High Dose ◽  
Allogeneic Bone ◽  
Primary Role ◽  
Allogeneic Marrow

Persistence of the underlying malignancy remains the major obstacle limiting the success of high-dose chemoradiotherapy with allogeneic bone marrow transplantation (BMT) for lymphomas and multiple myeloma. We used the C3H 38C13 murine B-cell lymphoma, which expresses and secretes clonally derived Ig, the idiotype of which can serve as a tumor-specific antigen, to test the principle of transfer of tumor idiotype-specific immunity with BM. BALB/c marrow donors were twice immunized with 38C13-derived Ig, or with an isotype-matched control Ig, conjugated to keyhole limpet hemocyanin. Lethally irradiated C3H recipients reconstituted with marrow from idiotype immune, but not nonspecifically immune, donors demonstrated protection against subsequent lethal tumor challenge. The immunoprotective effect of immune allogeneic marrow was abrogated by T-cell depletion of the marrow graft before infusion. Low levels of serum anti-idiotypic antibody remained unaltered in recipients of T-cell-depleted immune marrow, consistent with a primary role for T-cell immunity in the cellular mechanism of this phenomenon. A modest therapeutic effect of immune allogeneic marrow was observed against 10 day, 1 cm established subcutaneous tumors, but only in combination with a booster immunization of the recipient post-BMT. These results provide the rationale for a novel strategy for enhancing the specific antitumor effect of allogeneic marrow grafts.

scholarly journals Brief Report: Transplantation of Allogeneic Canine Bone Marrow Stored at -80 C. in Dimethyl Sulfoxide

Blood ◽  
1969 ◽  
Vol 33 (6) ◽  
pp. 918-923 ◽  
Author(s):  
R. STORB ◽  
R. B. EPSTEIN ◽  
R. F. LE BLOND ◽  
R. H. RUDOLPH ◽  
E. D. THOMAS
Keyword(s):  
Bone Marrow ◽  
Dimethyl Sulfoxide ◽  
Red Cell ◽  
Cell Type ◽  
Litter Mate ◽  
Cytogenetic Studies ◽  
Unrelated Donors ◽  
Bone Marrow Engraftment ◽  
Allogeneic Marrow ◽  
Marrow Cells

Abstract Prompt initial bone marrow engraftment was observed in 10 lethally irradiated dogs receiving infusions of 9.8 to 30.0 x 109 allogeneic marrow cells stored at -80 C. in dimethyl sulfoxide. The 3 recipients of bone marrow from unrelated donors, mismatched by canine histocompatibility testing, subsequently rejected their grafts and died within 16 days with marrow hypoplasia. The 3 dogs with matched unrelated donors and the 4 with matched litter mate donors all showed sustained marrow engraftment. Evidence of marrow repopulation by allogeneic cells was obtained by cytogenetic studies in one and by change to donor red cell type in 3 instances.

Bone-Marrow Ablation and Allogeneic Marrow Transplantation in Acute Leukemia

1980 ◽  
Vol 302 (19) ◽  
pp. 1041-1046 ◽  
Author(s):  
Karl G. Blume ◽  
Ernest Beutler ◽  
Klaus J. Bross ◽  
Ram K. Chillar ◽  
Owen B. Ellington ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Acute Leukemia ◽  
Marrow Transplantation ◽  
Allogeneic Marrow Transplantation ◽  
Bone Marrow Ablation ◽  
Marrow Ablation ◽  
Allogeneic Marrow

PG27, an extract of Tripterygium wilfordii hook f, induces antigen-specific tolerance in bone marrow transplantation in mice

Blood ◽  
2000 ◽  
Vol 95 (2) ◽  
pp. 705-710 ◽  
Author(s):  
Yanfei Chen ◽  
Defu Zeng ◽  
Paul G. Schlegel ◽  
John Fidler ◽  
Nelson J. Chao
Keyword(s):  
Bone Marrow ◽  
Chinese Herb ◽  
Third Party ◽  
Tripterygium Wilfordii ◽  
Tripterygium Wilfordii Hook F ◽  
Graft Versus Host ◽  
Graft Versus Leukemia ◽  
Tripterygium Wilfordii Hook ◽  
Allogeneic Marrow ◽  
Specific Tolerance

PG27, an active fraction purified from an extract of a Chinese herb,Tripterygium wilfordii hook f, was used to prevent graft-versus-host disease (GVHD) in a murine model. Lethally irradiated BALB/c (H-2d) recipients of B10.D2 (H-2d) donor grafts were given daily intraperitoneal injections of PG27 (40 mg/kg per day) for the first 35 days after transplantation. Control mice were given daily injections of solvent vehicle (Ethanol and Cremophor EL). All the control recipients (15/15) died of GVHD within 90 days, but all the recipients given prophylactic treatment with PG27 (15/15) survived beyond 100 days without any signs of GVHD. Furthermore, the GVHD-free recipients were used as donors, and their bone marrow and spleen cells were transplanted into lethally irradiated normal BALB/c (same party) or lethally irradiated normal C3H (H-2k, third party) mice. Although 10 of 10 same-party recipients survived more than 100 days without any signs of GVHD, 10 of 10 third-party C3H recipients died of GVHD within 40 days. Further studies of PG27 in the murine BCL1 leukemia/lymphoma model demonstrated that animals treated with PG27 partially retained the graft-versus-leukemia (GVL) effect of the graft without GVHD. These results suggest that treatment with PG27 induces host-specific tolerance and retains the GVL effect of allogeneic marrow grafts.

Sign in / Sign up

Export Citation Format

Share Document